Molina Healthcare(MOH) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported an adjusted loss per share of $2.75 on $10.7 billion of premium revenue for Q4 2025, which was below expectations due to strong trend pressure in Medicare and Marketplace, along with retroactive items in Medicaid totaling $2 per share [6][19] - For the full year 2025, premium revenue was $43 billion, representing an 11% year-over-year growth, while adjusted earnings per share were $11.03, with a pretax margin of 1.6% [7][8] - The Medicaid MCR for Q4 was 93.5%, impacted by unfavorable retroactive premium rate actions, while the full year MCR was 91.8% with a pretax margin of 2.8% [7][21] Business Line Data and Key Metrics Changes - In Medicaid, the MCR for Q4 was 93.5%, and adjusting for retroactive items, it restates to 92.3% with a pretax margin of 2% [19][20] - The Medicare MCR for Q4 was 97.5%, reflecting elevated utilization of LTSS and high-cost drugs, while the full year MCR was 92.4% [21] - The Marketplace MCR for Q4 was 99%, impacted by elevated utilization and prior period claim settlements, with a full year MCR of 90.6% [22] Market Data and Key Metrics Changes - The company secured a historic RFP win in Florida, expected to yield $6 billion in annual run rate premium, complementing previous contract wins in Wisconsin, Georgia, and Texas, representing over $9 billion of Medicaid premium [10][11] - The company anticipates 2026 premium revenue of approximately $42 billion, slightly lower than 2025, driven by new contracts and planned reductions in the Marketplace segment [12][13] Company Strategy and Development Direction - The company aims to focus on dual-eligible members in Medicare, planning to exit the traditional MAPD product for 2027 [14] - The acquisition pipeline contains actionable opportunities, with the company remaining opportunistic about deploying capital for accretive acquisitions [12] - The company expects Medicaid rates and medical cost trends to eventually reach equilibrium, with a forecast for low single-digit margins in Medicaid [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for the business despite disappointing 2025 results, citing that the medical cost trend in 2025 was an anomaly [10][17] - The company believes that Medicaid rates are underfunded by 300-400 basis points and anticipates that actuarial soundness will prevail, allowing for target margins to be achieved [17][18] - Management expects 2026 to be a trough year for managed Medicaid margins, projecting a low single-digit margin rather than losses [17] Other Important Information - The company reported a capital foundation remains strong, with a parent company cash balance of approximately $223 million at year-end [23] - The adjusted G&A ratio for Q4 was 6.9%, reflecting disciplined cost management [22] Q&A Session Summary Question: Variance in Medicaid margins across states and potential exit considerations - Management indicated that rates are generally underfunded across the portfolio, and there are no states where an exit is being contemplated [37] - The negative retro adjustments in California were due to situational factors, including a retroactive corridor for undocumented populations and a risk adjustment update [38][39] Question: Adjustments to benefit design in Medicaid - Management noted some sporadic adjustments to benefit design but emphasized that there is no wholesale shift occurring [48] Question: Membership attrition assumptions for 2026 - Management projected a 2% membership attrition, believing that the effects of redetermination are largely over [51][54] Question: Size of Medicaid expansion enrollment and attrition sources - The Medicaid expansion population is about 1.3 million members, with expected attrition of 15%-20% due to new policies [59][60] Question: Potential negative dynamics affecting 2026 guidance - Management acknowledged that while there are potential upside components, they believe rates at 4% are a floor, with no significant downside expected [64]